/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting
Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Research To Practice | Oncology Videos · Sep 17, 2026

Experts review ASCO 2026 data, highlighting potential "cures" in endometrial cancer and new ADCs for ovarian and cervical cancers.

Patient-Led Advocacy Is Key for Opportunistic Salpingectomy Adoption

For opportunistic salpingectomy to become widespread and reduce ovarian cancer rates, patients must be aware of the option and request it during other abdominal surgeries. This requires public education campaigns to create demand, complementing surgeon training.

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting thumbnail

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Research To Practice | Oncology Videos·2 months ago

Endometrial Cancer Trials Introduce "Cure Models" for Metastatic Disease

The RUBY trial's presentation on dMMR endometrial cancer used a "cure model" to quantify the likelihood of cure, a paradigm shift in patient communication for advanced solid tumors that offers statistical hope beyond just survival rates.

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting thumbnail

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Research To Practice | Oncology Videos·2 months ago

Conditional Survival Data Challenges Length of IO Maintenance Therapy

In dMMR endometrial cancer, data from the RUBY trial shows very few progressions after the first year. This "conditional survival" insight suggests that the current standard of 2-3 years of maintenance immunotherapy may be longer than necessary.

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting thumbnail

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Research To Practice | Oncology Videos·2 months ago

Clinicians Face Patient Resistance When Stopping "Lifeline" Immunotherapy

Despite data supporting limited-duration immunotherapy, physicians struggle to stop treatment. Patients in complete remission often view the well-tolerated therapy as a "lifeline," creating psychological barriers to de-escalating care.

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting thumbnail

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Research To Practice | Oncology Videos·2 months ago

New Ovarian Cancer Drugs Show Modest PFS but Greater OS Gains

A consistent pattern has emerged across new trials in platinum-resistant ovarian cancer (ROSELLA, KEYNOTE-B96, MIRASOL): therapies provide only modest progression-free survival (PFS) but a more substantial overall survival (OS) advantage, suggesting a shared biological effect.

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting thumbnail

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Research To Practice | Oncology Videos·2 months ago

Relacorilant Success Implies Steroids May Inhibit Chemotherapy Efficacy

The ROSELLA trial's success in boosting chemotherapy with a glucocorticoid receptor antagonist is thought-provoking. It suggests that routinely used steroids for managing side effects like nausea might inadvertently be diminishing chemotherapy's effectiveness across various cancers.

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting thumbnail

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Research To Practice | Oncology Videos·2 months ago

Clinicians Push HER2 Testing Boundaries for T-DXd Access

Driven by T-DXd's high efficacy and the known variability of IHC testing, oncologists are pragmatically retesting HER2-negative tumors and treating HER2-low (1+) patients. This blurs official indications to maximize patient access to a transformative drug.

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting thumbnail

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Research To Practice | Oncology Videos·2 months ago

ADC Sequencing Strategy Should Prioritize Varying Cytotoxic Payloads

In the evolving landscape of antibody-drug conjugates (ADCs), the critical factor for sequencing is likely the cytotoxic payload, not just the target antigen. A patient could respond to an ADC with a different payload after progressing on another, even if both target the same protein.

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting thumbnail

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Research To Practice | Oncology Videos·2 months ago